Thrombocythemia (THCYT)
Thrombocythemia (THCYT) is a disorder in which too many platelets are produced in the blood. With our pioneering efforts in THCYT research, we are at the forefront of developing cutting-edge diagnostic tools and therapeutics to facilitate the effective management of THCYT. As your reliable partner in THCYT research, we offer unmatched support to fulfill your scientific research needs.
Overview of THCYT
Thrombocythemia (THCYT), also known as thrombocytosis, is a hematological disorder characterized by an abnormal increase in platelet levels in the blood. Platelets play a crucial role in blood clotting, and their excessive production can lead to various complications. The annual incidence of THCYT is reported to be approximately 1.0 to 2.5 cases per 100,000 individuals.
Fig. 1 Bleeding mechanisms in individuals with essential thrombocythemia. (Awada, Hassan, et al., 2020)Pathogenesis of THCYT
THCYT can be classified into two main types: reactive thrombocythemia and essential thrombocythemia. Their pathogenesis varies.
| Disease Types | Pathogenesis | Proportion |
|---|---|---|
| Reactive Thrombocythemia | It is caused by infection, inflammatory diseases, or iron deficiency. | 88%-97% |
| Essential Thrombocythemia (ET) | It is caused by genetic mutations, such as those affecting the JAK2, CALR, or MPL genes. | Relatively rare |
Therapy Types of THCYT
Targeted Therapy
Targeted therapies aim to restore normal platelet production by selectively inhibiting dysregulated signaling pathways or genetic mutations. Ruxolitinib works by inhibiting JAK signaling and has shown promise in reducing platelet counts and improving symptoms in individuals with THCYT.
Gene Therapy
Since JAK2 gene mutations play a significant role in THCYT, gene therapy approaches targeting JAK2 have gained attention. Researchers are exploring strategies to deliver gene-editing tools, such as CRISPR-Cas9, to specifically correct the JAK2 mutation in affected cells, thereby restoring normal platelet production.
Immunotherapy
Immunotherapy harnesses the innate immune system to specifically target and eliminate abnormal platelet-producing cells. Among the immunomodulatory drugs, Interferon-alpha stands out as it effectively modulates platelet production and mitigates the risk of thrombotic events.
Our Services
As a frontrunner in the field of biological research and CRO services, our company is dedicated to offering holistic solutions for the diagnostics development and therapy research of THCYT. Through collaborations with industry experts, we have established all-encompassing platforms for rare diseases to facilitate THCYT therapy development.
Platforms of THCYT Therapy Development
Recognizing the significance of dependable animal models in THCYT disease research, our company is committed to offering animal model development services that facilitate preclinical research and aid in drug discovery endeavors.
Animal Models of THCYT
| Non-immune Models | ||||
|---|---|---|---|---|
| Non-immune models reduce platelet production through myelosuppression. Myelosuppressive drugs, such as cyclophosphamide and carboplatin, are commonly used to induce thrombocytopenia in animal models. | ||||
| Immune Models | ||||
| Our scientists induce thrombocytopenia via serum injection or antiplatelet monoclonal antibodies. These models are also called passive transfer models. In addition, we can develop secondary immune thrombocytopenia through chronic and acute infections and certain drug therapeutics, which lead to the production of antiplatelet antibodies. | ||||
| Optional Models |
|
|
||
| Genetically Engineered Models | ||||
| The emergence of genome editing technologies, such as CRISPR/Cas9, has revolutionized the field of animal model development. These tools enable precise genetic modifications, allowing researchers to introduce specific THCYT-associated mutations or edit relevant genes in animal models. | ||||
| Optional Models |
|
|
|
|
| Optional Species | Mice, Rats, Rabbits, Dogs Zebrafish, Non-human Primates (Macaques), Others | |||
With complete animal species resources, we can meet your diversified preclinical research including drug safety evaluation and pharmacokinetic analysis. If you are interested in our services, please feel free to contact us for more details and quotation information for related services.
References
- Awada, Hassan, et al. "Essential thrombocythemia and acquired von willebrand syndrome: the shadowlands between thrombosis and bleeding." Cancers 12.7 (2020): 1746.
- Kamali, H., et al. "Experimental models of thrombocytopenia in laboratory animals and their application in identifying the complications of chemotherapy drugs." Journal of Babol university of medical sciences 20.4 (2018): 48-58.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.